Press Releases

 Sign up for email alerts here

 

Date Title and Summary Additional Formats
Toggle Summary Genocea to Present at Jefferies 2018 Global Healthcare Conference
Presentation to be webcast live at 12:30 pm ET on June 8, 2018 CAMBRIDGE, Mass. , June 01, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer,
View HTML
Toggle Summary Genocea Reports First Quarter 2018 Financial and Operating Results
- Company files IND for lead neoantigen vaccine program, GEN-009 -  - ATLAS ™ platform continues to stand apart from in silico methods of neoantigen identification -  - Conference call today at 9 am ET - CAMBRIDGE, Mass. , May 10, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
View HTML
Toggle Summary Genocea to Host First Quarter 2018 Financial Results Conference Call & Webcast on May 10, 2018 at 9 a.m. ET
CAMBRIDGE, Mass. , May 04, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. ( NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, May 10, 2018 at 9:00 a.m.
View HTML
Toggle Summary Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009
- C ompany plans to initiate Phase 1/2a clinical program later this year -  - Top-line immune response data expected in the first half of 2019 - CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) --   Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer
View HTML
Toggle Summary Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods
- ATLAS data demonstrate in silico methods miss most empirically confirmed neoantigens - - ATLAS able to identify inhibitory neoantigens - - Mouse ATLAS melanoma model developed to study mechanism of inhibitory antigens - CAMBRIDGE, Mass. , April 18, 2018 (GLOBE NEWSWIRE) --   Genocea Biosciences,
View HTML
Toggle Summary Genocea to Present Data at Upcoming AACR Annual Meeting Further Highlighting ATLAS Platform Ability to Identify and Characterize Neoantigens for Cancer Vaccines
CAMBRIDGE, Mass. , April 09, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research ( AACR 2018 ), taking
View HTML
Toggle Summary Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing
CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced the appointment of Narinder Singh as senior vice president of pharmaceutical sciences and manufacturing. Mr.
View HTML
Toggle Summary Genocea to Present at Two March Investor Conferences
CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at two upcoming investor
View HTML
Toggle Summary Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
- GEN-009 neoantigen vaccine advancing to IND filing - - Balance sheet strengthened with $55m gross proceeds from January equity financing - - Conference call today at 9 am ET - CAMBRIDGE, Mass. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
View HTML
Toggle Summary NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences' Board of Directors
Follows NEA investment in Genocea during January 2018 concurrent equity financings
View HTML
Toggle Summary Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
CAMBRIDGE, Mass. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that it will host a conference call and live audio webcast on Thursday, February 15, 2018 at 9:00 a.m.
View HTML
Toggle Summary Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings
New Enterprise Associates ("NEA") and Vivo Capital significant investors in financing Genocea intends to elect an NEA representative to Genocea board of directors CAMBRIDGE, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers
View HTML
Toggle Summary Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants
CAMBRIDGE, Mass. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company that discovers and develops novel cancer vaccines, announced today that it intends to offer and sell in concurrent underwritten public offerings (i) shares of its common stock
View HTML
Toggle Summary Genocea to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will participate in a fireside chat at the 29th Annual Piper
View HTML
Toggle Summary Genocea to Present at Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass. , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences , Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark , president and chief executive officer, will present a company overview at the Stifel 2017 Healthcare
View HTML